HighVista Strategies’s Immunocore IMCR Stock Holding History

HighVista Strategies’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Sell	43,185 -15,512	-26%	-$459K	0.31%	95
2026 Q1	$1.77M	Buy	58,697 +25,699	+78%	+$831K	0.49%	62
2025 Q4	$1.15M	Buy	+32,998	New	+$1.16M	0.3%	98
2024 Q2	–	Sell	-34,762	Closed	-$2.26M	–	143
2024 Q1	$2.26M	Sell	34,762 -6,865	-16%	-$471K	0.81%	41
2023 Q4	$2.84M	Buy	41,627 +1,823	+5%	+$94.8K	1.03%	32
2023 Q3	$2.07M	Sell	39,804 -4,290	-10%	-$254K	0.96%	29
2023 Q2	$2.64M	Buy	44,094 +30,900	+234%	+$1.76M	1.21%	23
2023 Q1	$652K	Hold	13,194	–	–	0.53%	64
2022 Q4	$753K	Sell	13,194 -3,394	-20%	-$191K	0.45%	66
2022 Q3	$779K	Buy	+16,588	New	+$791K	0.44%	60

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

HighVista Strategies's IMCR Position: Q2 2026 in Review

HighVista Strategies reduced its Immunocore (IMCR) stake by 26% in Q2 2026, selling an estimated $459K and leaving 43,185 shares worth $1.37M. The position accounts for 0.31% of the portfolio, ranked #95.

HighVista Strategies first reported a position in IMCR in Q3 2022 and has held it in 10 quarters since. The position peaked at $2.84M in Q4 2023. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

HighVista Strategies held 43,185 shares of Immunocore worth $1.37M as of Q2 2026.
HighVista Strategies sold 15,512 Immunocore shares in Q2 2026, an estimated $459K.
Immunocore made up 0.31% of HighVista Strategies's portfolio in Q2 2026, its #95 holding.
HighVista Strategies first reported a position in Immunocore in Q3 2022 and has held it in 10 quarters since.
HighVista Strategies's Immunocore position peaked at $2.84M in Q4 2023.
135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.